Moosa Mohammadi Lab
Tel:  (212) 263-7122
Fax:  (212) 263-7133
Add:  MSB 425 - 431, 550 First Ave, New York, NY 10016
  1. Conversion of a Paracrine Fibroblast Growth Factor into an Endocrine Fibroblast Growth Factor. J Biol Chem. 2012 Jun 25; doi:10.1074 / jbc.M112.342980
  2. FGF23 Acts Directly on Renal Proximal Tubules to Induce Phosphaturia through Activation of the ERK1/2-SGK1 Signaling Pathway. Bone. 27 May 2012; BON-09650; No. of pages: 8; 4C: 3, 4, 5, 6, 7
  3. Klotho Co-Receptors Inhibit Signaling by Paracrine FGF8 Subfamily Ligands. Molecular and Cellular Bioliology. 26 March 2012; 10.1128/MCB.06603-11
  4. The Structural Biology of the FGF19 Subfamily. Advances in Experimental Medicine and Biology. 2012
  5. Genetic Overlap in Kallmann Syndrome, Combined Pituitary Hormone Deficiency, and Septo-Optic Dysplasia. J Clin Endocrinol Metab. 2012 Feb 8
  6. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A. 2012 Feb 6
  7. Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1. J Biol Chem. 2012 Jan 27;287(5):3067-78
  8. The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition. Structure. 2012 Jan 11;20(1):77-88
  9. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol. 2011 Aug;301(2):F371-7
  10. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest. 2011 Aug 1;121(8):3220-32
  11. Urothelial Tumor Initiation Requires Deregulation of Multiple Signaling Pathways: Implications in Target-based Therapies. Carcinogenesis. 2012 Jan 27
  12. Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse. Molecular Endocrinology, doi:10.1210/me.2010-0142
  13. Influence of Heparin Mimetics on the Assembly of the FGF - FGFR4 Signaling Complex. J Biol Chem. 2010 Jun 14
  14. Nonsense Mutations in FGF8 Gene Causing Different Degrees of Human Gonadotropin-Releasing Deficiency. J Clin Endocrinol Metab. 2010 May 12
  15. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2009 Dec 4
  16. Impaired Fibroblast Growth Factor Receptor 1 Signaling as a Cause of Normosmic Idiopathic Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2009 Oct 9
  17. Differential Interactions of FGFs with Heparan Sulfate Control Gradient Formation and Branching Morphogenesis. Sci Signal. 2009 Sep 15;2(88):ra55
  18. Compositional Analysis of Heparin/Heparan Sulfate Interacting with Fibroblast Growth Factor • Fibroblast Growth Factor Receptor Complexes. Biochemistry. 2009 Sep 8;48(35):8379-86
  19. Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix. Mol Cell Biol. 2009 Sep;29(17):4663-78
  20. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. PNAS June 30, 2009 vol. 106 no. 26 10853-10858
  21. Crystal Structure of a Fibroblast Growth Factor Homologous Factor (FHF) Defines a Conserved Surface on FHFs for Binding and Modulation of Voltage-gated Sodium Channels. J. Biol. Chem., Vol. 284, Issue 26, 17883-17896, June 26, 2009
  22. Graded levels of FGF protein span the midbrain and can instruct graded induction and repression of neural mapping labels. Neuron. 2009 Jun 25;62(6):773-80
  23. FGF23 Decreases Renal NaPi-2a and NaPi-2c Expression and Induces Hypophosphatemia In Vivo Predominantly Via FGF Receptor 1. Am J Physiol Renal Physiol (June 10, 2009). doi:10.1152/ajprenal.90742.2008
  24. The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery 8, 235-253 (March 2009) | doi:10.1038/nrd2792
  25. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 2009 Feb;23(2):433-41. Epub 2008 Oct 3
  26. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res. 2009 Jan;7(1):41-54
  27. A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19660-5. Epub 2008 Dec 5
  28. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol. 2008 Aug 11;182(3):459-65
  29. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J. Clin. Invest. 118(8): 2822-2831 (2008)
  30. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metabolism. Volume 8, Issue 1, 2 July 2008, Pages 77-83
  31. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous β-catenin. Human Mutation, 2008 Mar;29(3):390-7
  32. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. doi:10.1172/JCI32409, 2007 Nov 8
  33. A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases. Molecular Cell, Vol 27, 717-730, 07 September 2007
  34. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117:2684-2691 (2007)
  35. Tissue-specific expression of beta KLOTHO and fibroblast growth factor receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem, 10.1074/jbc.M704165200
  36. Endocrine Regulation of the Fasting Response by PPARN1-Mediated Induction of Fibroblast Growth Factor 21. Cell Metabolism, Vol 5, 415-425, 06 June 2007
  37. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007 May 21
  38. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(18): 7432-7
  39. Impaired FGF signaling contributes to cleft lip and palate. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 4512
  40. Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of FGF19 Subfamily Members. Mol. Cell. Biol. 2007; doi:10.1128/MCB.02249-06
  41. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest. 2007 January 18. doi: 10.1172/JCI29884
  42. Hedgehogs like it sweet, too. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 17069
  43. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. Journal of biological chemistry. 2006; 281:867
  44. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes & development. 2006; 20: 185
  45. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 6281
  46. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Molecular & cellular endocrinology. 2006; 254-255: 60
  47. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. Journal of biological chemistry. 2006; 281: 15694
  48. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Molecular & cellular biology. 2005; 25: 671
  49. Understanding the molecular basis of apert syndrome. Plastic & reconstructive surgery. 2005; 115: 264
  50. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs. Current opinion in structural biology. 2005; 15: 506
  51. Structural basis for fibroblast growth factor receptor activation. Cytokine & growth factor reviews. 2005; 16: 107
  52. Identification of phosphopeptides by MALDI Q-TOF mass spectrometry in positive and negative ion modes after methyl esterification. Molecular & cellular proteomics. 2005; 4: 809
  53. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology. 2005; 146: 4647
  54. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Human molecular genetics. 2004; 13: 2313
  55. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry. 2004; 43: 4724
  56. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Human molecular genetics. 2004; 13: 69
  57. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 935
  58. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. Journal of biological chemistry. 2003; 278: 34226
  59. Structure-based mutational analyses in FGF7 identify new residues involved in specific interaction with FGFR2IIIb. FEBS letters. 2003; 552: 150
  60. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 2266
  61. Synthesis of sulfosucrose derivatives for evaluation as regulators of fibroblast growth factor activity. Tetrahedron letters. 2002; 43: 8047
  62. Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Molecular & cellular biology. 2002; 22: 7184
  63. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Molecular & cellular biology. 2001; 21: 5946
  64. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 7182
  65. Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition. Journal of biological chemistry. 2001; 276: 4322
  66. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer research. 2000; 60: 4152
  67. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell. 2000; 101: 413
  68. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Molecular cell. 2000; 6: 743
  69. Structural basis for FGF receptor dimerization and activation. Cell. 1999; 98: 641
  70. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. Molecular biology of the cell. 1999; 10: 23-33
  71. Autoregulatory mechanisms in protein-tyrosine kinases. Journal of biological chemistry. 1998; 273: 11987
  72. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO journal. 1998; 17: 5896
  73. Differential pre- and postsynaptic modulation of chemical transmission in the squid giant synapse by tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 1990
  74. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997; 276: 955
  75. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Molecular & cellular biology. 1996; 16: 977
  76. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell. 1996; 86: 577
  77. Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase Cgamma1. Journal of biological chemistry. 1996; 271: 31154
  78. Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis. Journal of biological chemistry. 1995; 270: 5065
  79. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995; 373: 536-539
  80. Signal transduction by the α6β4 integrin: distinct β4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. EMBO journal. 1995; 14: 4470
  81. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. Journal of biological chemistry. 1994; 269: 17056
  82. Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 cells. Journal of biological chemistry. 1994; 269: 14419
  83. Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. Biochemistry. 1993; 32: 8742
  84. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science. 1993; 260: 1953
  85. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature. 1992; 358: 681
  86. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase Cγ. EMBO journal. 1992; 11: 559
  87. Role of SH2-containing proteins in cellular signaling by receptor tyrosine kinases. Cold Spring Harbor symposia on quantitative biology. 1992; 57: 67
  88. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Molecular & cellular biology. 1991; 11: 5068
  89. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell. 1991; 65: 83
  90. The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-γ. EMBO journal. 1990; 9: 4375
  91. Generation of recombinant cytoplasmic domain of epidermal growth factor receptor with intrinsic protein tyrosine kinase activity. Cell growth & differentiation. 1990; 1:191-200